Post-earnings recap
Reported
Thu, Oct 25, 2012
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
BioMarin's earnings report showed a significant positive surprise on EPS, indicating better-than-expected loss management. However, the stock reacted negatively, declining by 0.44%. This could suggest that investors are cautious about the lack of revenue details and future guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.04 | N/A | +80.58% |
| Revenue | N/A | N/A | N/A |
Management remains optimistic about the company's future, particularly regarding its clinical pipeline. However, they did not provide any updated guidance for upcoming quarters.
Management highlighted progress in ongoing clinical trials.
They expressed confidence in the pipeline despite current losses.
No specific guidance was provided for future quarters.